Expert Opinion on Emerging Drugs
Volume 27, 2022 - Issue 3
Open access
2,050
Views
0
CrossRef citations to date
0
Altmetric
Review
Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma
Udo RudloffRare Tumor Initiative, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USACorrespondence[email protected]
View further author information
View further author information
Pages 345-368
|
Received 06 Jun 2022, Accepted 06 Oct 2022, Published online: 03 Nov 2022
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.